GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Behavioral: survey; Behavioral: No treatment given

Study type: Observational

Funder types: Industry

Identifiers

NCT01950637

U1111-1136-2536 (Other Identifier)

GAPP2

Details and patient eligibility

About

This study is conducted Asia, Europe and North America. The aim of this study is to describe insulin therapy adherence and the burden of non-adherence on patient functioning, well-being and diabetes management.

Enrollment: 4,000 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• PATIENTS WITH T2DM:
• Diagnosed with type 2 diabetes by a healthcare professional
• Currently being treated with insulin medication, excluding premix insulin treatment
• Age at least 40 years
• Diagnosed as having type 2 diabetes over the age of 40
• HCPs:
• Primary care physician, diabetes specialist (diabetologist/endocrinologist) or diabetes specialist nurse/diabetes nurse educator
• Have a minimum of 2 years experience within current speciality
• See a minimum of 20 type 2 diabetes patients per month (40 for diabetes specialists), of which at least 10 per month must be on modern (analogue) inulins

Trial design

4,000 participants in 2 patient groups

Patients with type 2 diabetes mellitus (T2DM)

Treatment:

Behavioral: No treatment given

Healthcare professionals (HCPs)

Treatment:

Behavioral: survey